B

중앙백신

072020KOSDAQ기초 의약물질 제조업

56.0 / 100

Reference Date: 2026-06-10

Financial Score25.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Declined 5.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Central Vaccine is a company specializing in the development and production of animal vaccines and biological products, focusing on disease prevention and control in the livestock industry. Recent outbreaks of African Swine Fever and Highly Pathogenic Avian Influenza have increased demand for vaccines, necessitating the development of new products to counteract the diminishing efficacy of existing ones. The company is expanding into new markets, including China and Brazil, to broaden its global presence.

Number of Employees

194people

Average Salary

57.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.31Industry Average 27.716.5Point

Lower than industry avg (good)

PBR
0.84Industry Average 1.747.0Point

Half of industry avg (excellent)

ROE
5.89Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
5.08Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼2.6% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 6.3% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 9,390Won52-week high 10,14052-week low 8,780
1-month return2.0Point

1m -5.06% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15